AbbVie hands over $20M for Alzheimer's, Parkinson's drugs; Autolus boosted by a PIM
AbbVie is paying $20 million to buy in new drug candidates from UK biotech Mission Therapeutics, which will aim to go …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
